Immucell (ICCC) Operating Expenses (2010 - 2026)

Immucell (ICCC) has reported Operating Expenses for 17 consecutive years, with $502288.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses fell 77.66% year-over-year to $502288.0; the trailing twelve-month figure through Jun 2026 stood at $8.1 million (down 8.94% YoY), and the FY2025 full-year result was $9.8 million, up 2.24% from the prior year.
• Operating Expenses eased to $502288.0 in Q2 2026 per ICCC's latest filing, from $3.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $3.0 million in Q4 2025 and bottomed at $502288.0 in Q2 2026.
• Historically, Operating Expenses has averaged $2.3 million across 5 years, with a median of $2.4 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Operating Expenses soared 34.29% in 2025, then slumped 77.66% in 2026.
• Over 5 years, Operating Expenses stood at $2.6 million in 2022, then declined by 6.66% to $2.5 million in 2023, then declined by 9.82% to $2.2 million in 2024, then surged by 34.29% to $3.0 million in 2025, then plunged by 83.08% to $502288.0 in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $502288.0, $3.0 million, and $2.3 million for Q2 2026, Q4 2025, and Q3 2025 respectively.